

Icade Santé SAS

A *société par actions simplifiée* established under the laws of the Republic of France having a share capital of €577,412,290.25 with its registered office at 27, Rue Camille Desmoulins, 92130 Issy-les-Moulineaux, France, 318 251 600 RCS Nanterre

APPROVAL OF THE PROPOSED CHANGE OF CORPORATE FORM AND CORPORATE PURPOSE OF ICADE SANTÉ BY THE HOLDERS OF THE FOLLOWING NOTES

€500,000,000 0.875 per cent. Notes due
4 November 2029 issued on 4 November 2019
ISIN: FR0013457967 – Common Code: 207521400
(the “Notes”)

issued by
Icade Santé SAS
(the “Company”)

Issy-les-Moulineaux, France, on 27 July 2021,

The Company hereby announces that the proposed change of its corporate form and corporate purpose in the context of its contemplated initial public offering has been approved by the general meeting of the holders of the Notes (individually a “**Noteholder**” and collectively the “**Noteholders**”) held on 27 July 2021 on first convocation (the “**General Meeting**”).

The resolutions (the “**Resolutions**”) submitted to, and approved by, the General Meeting, were the following:

- approval of the change of the Company’s corporate form from a *société par actions simplifiée* to a *société anonyme à conseil d’administration*, with effect on the date of approval by the French *Autorité des marchés financiers* of the prospectus relating to the admission of the Company’s shares to trading on the regulated market of Euronext Paris;
- approval of the change of the Company’s corporate purpose to, *inter alia*, extend the corporate purpose of the Company to international activities, investment in any kind of institutions for the elderly and the provision of certain assistance and services to its subsidiaries, with effect on the date of approval by the French *Autorité des marchés financiers* of the prospectus relating to the admission of the Company’s shares to trading on the regulated market of Euronext Paris; and
- filing at Icade Santé’s registered office of the attendance sheet, the relevant powers of represented Noteholders set out in the participation form and the minutes of the General Meeting.

The Company will pay to each Noteholder an amount in cash in euros equal to 0.05% of the aggregate nominal amount of the Notes held by such Noteholder (the “**Consent Fee**”).

For the avoidance of doubt, any and all Noteholders shall be entitled to receive the Consent Fee, whether they voted or not at the General Meeting and, if they voted, whether they voted or not in favour of the Resolutions.

Subject to and as provided above, the right of each Noteholder to receive the Consent Fee will be evidenced by the entries in the books of the relevant intermediary institution entitled to hold, directly or indirectly, accounts on behalf of its customers with Euroclear France and includes Euroclear Bank S.A./N.V. and Clearstream Banking S.A. of the name of such Noteholder on the second business day in Paris preceding the date set for the General Meeting (i.e. on 23 July 2021 at 00.00 (midnight), Paris Time).

The payment of the Consent Fee is expected to take place on or about 29 July 2021.

For any additional information about this communication, please contact:

ICADE SANTÉ

27, Rue Camille Desmoulins
92130 Issy les Moulineaux
France

Tel: +33 1 41 57 71 24 / +33 1 41 57 79 02

Attention: Helga Camalon / Etienne Maurer

Email: helga.camalon@icade.fr / etienne.maurer@icade.fr

CENTRALIZING AGENT

Société Générale Securities Services

32, rue du champ de tir
CS 30812

44308 NANTES Cedex 03

Tel: +33 2 51 85 52 49

Email: agobligataire.fr@socgen.com